In the registry-based, cohort study AvoidEx, data was collected from German healthcare insurance claims and Swedish medical records of COPD patients ≥40 years. All participants had their first COPD diagnosis during 2010-2017. Overall, 250,723 COPD patient from Germany and 27,178 COPD patients from Sweden were included. Patients were divided into 4 groups (i.e. none, 1 moderate, 1 severe, ≥ 2 moderate to severe) according to the baseline exacerbation 12 months pre-index (which is based on the exacerbation classification). The follow-up period lasted up to 9 years.
In German patients without baseline exacerbations, 19.0% (18.9-19.2%) had exacerbations after 1-year follow-up and 35.9% (35.7-36.1%) after 3 years. In Sweden, corresponding numbers were 22.5% (21.9-23.1%) and 39.4% (38.7-40.1%), respectively. After 3 years, cumulative exacerbation risk was 59.1% (58.5-59.7%), 58.1% (56.1-60.1%), and 84.1% (83.6-84.5%) in German patients with 1 moderate, 1 severe, and ≥2 moderate-to-severe exacerbations at baseline, respectively. Corresponding numbers in the Swedish population were 53.6% (51.7-55.5%), 66.6% (62.6-70.7%), and 84.1% (82.8-85.4%), respectively (see Figure). “As you can see, there is a stepwise increase: patients who had a lower exacerbation rate in the past had a lower risk of exacerbations in the future and the risk goes up depending on the exacerbation history,” explained Prof. Claus Vogelmeier (University Clinic Giessen and Marburg, Germany).
Figure: Results show that patients with previous exacerbations have a much higher risk of future exacerbations [1]

In total, more than 1 out of 3 patients without baseline COPD exacerbation experienced exacerbation(s) during the 3-year follow up. In addition, more than half of those with 1 moderate baseline exacerbation experienced subsequent exacerbation(s), with an even higher risk in patients with frequent or severe baseline exacerbations. Yet, even patients with only 1 moderate baseline exacerbation had more subsequent exacerbations compared with those without baseline exacerbations. Patients with no history of exacerbations had also a much longer time until the next subsequent exacerbation during follow-up.
“I think this data very nicely supports earlier data under very different circumstances, because this data used medical data and insurance data from a very big cohort. But all this information stresses that exacerbation history is a self-fulfilling prophecy for future events,” Prof. Vogelmeier concluded.
- Vogelmeier C. Risk of future exacerbations among COPD patients – A real-world register-based cohort study (AvoidEx). Abstract 4189, ERS International Virtual Congress 2020, 7-9 Sept.
Posted on
Previous Article
« Singing training effective as physical rehabilitation in COPD Next Article
Nasal high-flow therapy: a novel treatment option for hypercapnic COPD patients »
« Singing training effective as physical rehabilitation in COPD Next Article
Nasal high-flow therapy: a novel treatment option for hypercapnic COPD patients »
Table of Contents: ERS 2020
Featured articles
COVID-19 and the Lung
COVID-19 infections: Bronchoscopy provides additional diagnostic certainty
COVID-19 vaccines: An ongoing race
COVID-19: What is the risk of reinfection?
COVID-19 App: The Dutch experience
Secondary pulmonary fibrosis: a possible long-term effect of severe COVID-19
COVID-19 survivors benefit from structured follow-up
Early pulmonary rehabilitation post-COVID-19 aids recovery
Asthma – What's New
Mild asthma: A fundamental change in management
Dupilumab shows long-term efficacy in asthma patients
Severe asthma: Oral corticosteroids maintenance therapy associated with toxicity
First-in-class tyrosine kinase inhibitor shows promise in severe asthma
Predicting individual effectiveness of biologics in severe asthma
IL-5 antagonist showed efficacy in chronic rhinosinusitis with nasal polyps
Treatment according to genotype: The future of asthma therapy?
COPD – The Beat Goes On
The role of chronic symptoms as early biomarkers of COPD development
Urgent call for studies in COPD patients aged 40-60 years
Nasal high-flow therapy: a novel treatment option for hypercapnic COPD patients
Exacerbation history is a reliable predictor of future exacerbations
Singing training effective as physical rehabilitation in COPD
Current prediction tools underestimate exacerbation risk of severe COPD patients
Exercise and Sleep: From Impaired Function to New Therapeutic Strategies
CPAP withdrawal has negative consequences for sleep apnoea patients
Physical activity improves AHI in sleep apnoea patients
The Tobacco Epidemic: From Vaping to Cannabis
Poly-use of nicotine products and cannabis: a deadly combination
E-cigarettes: A source of chronic lung inflammation
Social smoking: Do not underestimate the risks
Chronic Cough – State of the Art
LEAD study shows multiple phenotypes in many chronic cough patients
First-in-class P2X3 receptor antagonist shows promise for chronic cough treatment
Lung Cancer Detection
Lung cancer screening: Most patients not eligible 1-2 years prior to diagnosis
Distinct changes in lung microbiome precede clinical diagnosis of lung cancer
Best of Posters
Smartphone-based cough detection helpful in predicting asthma deterioration
Reduced lung function associated with cognitive decline in the elderly
Longer hospital stay and fewer transplants for frail ILD patients
Related Articles
August 17, 2022
Thoracic ultrasound: a new diagnostic imaging tool in RA-ILD?

June 22, 2022
EULAR 2022 Highlights Podcast
August 17, 2022
Update on treatment of fibrotic ILD
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com